Mouse Anti-HDAC9 Recombinant Antibody (EG1501) (CBMAB-EN1795-LY)

Name: Mouse Anti-HDAC9 Recombinant Antibody (EG1501)
SKU: CBMAB-EN1795-LY
Rating: 5 (1 reviews)

See all HDAC9 antibodies

Compare Online Inquiry

Datasheet

SDS

Request for COA

Datasheet Target References Q & As Review & reward Protocols Associated Products

Basic Information

Host Animal

Mouse

Clone

EG1501

Application

ELISA, WB

Immunogen

Recombinant fragment of Human HDAC9 (C-terminus).

Specificity

Human

Antibody Isotype

IgG

Clonality

Monoclonal

Application Notes

The COA includes recommended starting dilutions, optimal dilutions should be determined by the end user.

Formulations & Storage [For reference only, actual COA shall prevail!]

Format

Liquid

Storage

Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freezethaw cycles.

More Infomation

Target

Full Name

Histone Deacetylase 9

Introduction

Histones play a critical role in transcriptional regulation, cell cycle progression, and developmental events. Histone acetylation/deacetylation alters chromosome structure and affects transcription factor access to DNA. The protein encoded by this gene has sequence homology to members of the histone deacetylase family. This gene is orthologous to the Xenopus and mouse MITR genes. The MITR protein lacks the histone deacetylase catalytic domain. It represses MEF2 activity through recruitment of multicomponent corepressor complexes that include CtBP and HDACs. This encoded protein may play a role in hematopoiesis. Multiple alternatively spliced transcripts have been described for this gene but the full-length nature of some of them has not been determined. [provided by RefSeq, Jul 2008]

Entrez Gene ID

9734

UniProt ID

Q9UKV0

Alternative Names

Histone Deacetylase 9; Histone Deacetylase 7B; EC 3.5.1.98; HDAC7B; HDAC7; HD7b; HDRP; MITR; HD7; HD9;

Function

Responsible for the deacetylation of lysine residues on the N-terminal part of the core histones (H2A, H2B, H3 and H4). Histone deacetylation gives a tag for epigenetic repression and plays an important role in transcriptional regulation, cell cycle progression and developmental events. Represses MEF2-dependent transcription.

Isoform 3 lacks active site residues and therefore is catalytically inactive. Represses MEF2-dependent transcription by recruiting HDAC1 and/or HDAC3. Seems to inhibit skeletal myogenesis and to be involved in heart development. Protects neurons from apoptosis, both by inhibiting JUN phosphorylation by MAPK10 and by repressing JUN transcription via HDAC1 recruitment to JUN promoter.

Biological Process

B cell activation Source: UniProtKB
B cell differentiation Source: UniProtKB
Cellular response to insulin stimulus Source: BHF-UCL
Cholesterol homeostasis Source: ARUK-UCL
Chromatin organization Source: UniProtKB-KW
Heart development Source: BHF-UCL
Histone deacetylation Source: BHF-UCL
Histone H3 deacetylation Source: BHF-UCL
Histone H4 deacetylation Source: BHF-UCL
Histone H4-K16 deacetylation Source: ARUK-UCL
Inflammatory response Source: UniProtKB
Negative regulation of cytokine production Source: ARUK-UCL
Negative regulation of lipoprotein lipase activity Source: ARUK-UCL
Negative regulation of transcription, DNA-templated Source: BHF-UCL
Negative regulation of transcription by RNA polymerase II Source: BHF-UCL
Peptidyl-lysine deacetylation Source: BHF-UCL
Positive regulation of cell migration involved in sprouting angiogenesis Source: BHF-UCL
Regulation of skeletal muscle fiber development Source: UniProtKB
Regulation of striated muscle cell differentiation Source: UniProtKB

Cellular Location

Nucleus

Involvement in disease

A chromosomal aberration involving HDAC9 is found in a family with Peters anomaly. Translocation t(1;7)(q41;p21) with TGFB2 resulting in lack of HDAC9 protein.

PTM

Phosphorylated on Ser-220 and Ser-450; which promotes 14-3-3-binding, impairs interaction with MEF2, and antagonizes antimyogenic activity. Phosphorylated on Ser-240; which impairs nuclear accumulation (By similarity). Isoform 7 is phosphorylated on Tyr-1010. Phosphorylated by the PKC kinases PKN1 and PKN2, impairing nuclear import.
Sumoylated.

Goo, B., Ahmadieh, S., Zarzour, A., Yiew, N. K., Kim, D., Shi, H., ... & Weintraub, N. L. (2022). Sex-dependent role of adipose tissue HDAC9 in diet-induced obesity and metabolic dysfunction. Cells, 11(17), 2698.

Brancolini, C., Di Giorgio, E., Formisano, L., & Gagliano, T. (2021). Quis custodiet ipsos custodes (Who controls the controllers)? Two decades of studies on HDAC9. Life, 11(2), 90.

Das, S., & Natarajan, R. (2020). HDAC9: An inflammatory link in atherosclerosis. Circulation research, 127(6), 824-826.

Prestel, M., Prell-Schicker, C., Webb, T., Malik, R., Lindner, B., Ziesch, N., ... & Dichgans, M. (2019). The atherosclerosis risk variant rs2107595 mediates allele-specific transcriptional regulation of HDAC9 via E2F3 and Rb1. Stroke, 50(10), 2651-2660.

Xiong, K., Zhang, H., Du, Y., Tian, J., & Ding, S. (2019). Identification of HDAC9 as a viable therapeutic target for the treatment of gastric cancer. Experimental & molecular medicine, 51(8), 1-15.

Malhotra, R., Mauer, A. C., Lino Cardenas, C. L., Guo, X., Yao, J., Zhang, X., ... & O’Donnell, C. J. (2019). HDAC9 is implicated in atherosclerotic aortic calcification and affects vascular smooth muscle cell phenotype. Nature genetics, 51(11), 1580-1587.

Lino Cardenas, C. L., Kessinger, C. W., Cheng, Y., MacDonald, C., MacGillivray, T., Ghoshhajra, B., ... & Lindsay, M. E. (2018). An HDAC9-MALAT1-BRG1 complex mediates smooth muscle dysfunction in thoracic aortic aneurysm. Nature communications, 9(1), 1009.

Hu, Y., Sun, L., Tao, S., Dai, M., Wang, Y., Li, Y., & Wu, J. (2019). Clinical significance of HDAC9 in hepatocellular carcinoma. Cellular and Molecular Biology, 65(4), 23-28.

Huang, Y., Jian, W., Zhao, J., & Wang, G. (2018). Overexpression of HDAC9 is associated with poor prognosis and tumor progression of breast cancer in Chinese females. OncoTargets and therapy, 2177-2184.

Li, L., Liu, W., Wang, H., Yang, Q., Zhang, L., Jin, F., & Jin, Y. (2018). Mutual inhibition between HDAC9 and miR-17 regulates osteogenesis of human periodontal ligament stem cells in inflammatory conditions. Cell death & disease, 9(5), 480.

Ask a question We look forward to hearing from you.

0 reviews or Q&As

Purchasing FAQs
Technical FAQs

Have you used Mouse Anti-HDAC9 Recombinant Antibody (EG1501)?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon

$30 eGift Card
Submit a review

Please try the standard protocols which include: protocols, troubleshooting and guide.

Enzyme-linked Immunosorbent Assay (ELISA)
Flow Cytometry
Immunofluorescence (IF)
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Enzyme Linked Immunospot (ELISpot)
Proteogenomic
Other Protocols

Related Products

Mouse Anti-HDAC9 Monoclonal Antibody (CBFYH-3045) (CAT#: CBMAB-H1824-FY)

Rabbit Anti-HDAC9 Recombinant Antibody (CBNH-062) (CAT#: CBMAB-R4387-CN)

Mouse Anti-HDAC9 (AA 181-460) Recombinant Antibody (CBFYH-0895) (CAT#: CBMAB-H1825-FY)

Mouse Anti-HDAC9 Recombinant Antibody (CBFYH-0896) (CAT#: CBMAB-H0669-FY)

Mouse Anti-HDAC9 (AA 481-570) Recombinant Antibody (CBFYH-0898) (CAT#: CBMAB-H1827-FY)

Mouse Anti-HDAC9 Recombinant Antibody (CBT3225) (CAT#: V2LY-0625-LY282)

Isotype control

For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Online Inquiry

Request bulk or custom quote Second antibody and isotype control

Contact us

Tel: (USA)
(UK)
Fax:

Global Locations

Email:

Online Inquiry